Literature DB >> 22882891

Chapter 4: Development of the counterfactual smoking histories used to assess the effects of tobacco control.

Theodore R Holford1, Lauren Clark.   

Abstract

Publication of the Surgeon General's Report in 1964 marshaled evidence of the harm to public health caused by cigarette smoking, including lung cancer mortality, and provided an impetus for introducing control programs. The purpose of this article is to develop estimates of their effect on basic smoking exposure input parameters related to introduction of the report. Fundamental inputs used to generate exposure to cigarettes are initiation and cessation rates for men and women, as well as the distribution of the number of cigarettes smoked per day. These fundamental quantities are presented for three scenarios: actual tobacco control in the United States; no tobacco control in which the experience before 1955 was assumed to continue; and complete tobacco control in which all smoking ceased following publication of the report. These results were derived using data from National Health Interview Surveys, and they provide basic input parameters for the Smoking History Generator used by each of the lung cancer models developed by the Cancer Intervention and Surveillance Modeling Network.
© 2012 Society for Risk Analysis.

Entities:  

Mesh:

Year:  2012        PMID: 22882891      PMCID: PMC3490210          DOI: 10.1111/j.1539-6924.2011.01759.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  7 in total

1.  Flexible regression models with cubic splines.

Authors:  S Durrleman; R Simon
Journal:  Stat Med       Date:  1989-05       Impact factor: 2.373

2.  Effects of the antismoking campaign: an update.

Authors:  K E Warner
Journal:  Am J Public Health       Date:  1989-02       Impact factor: 9.308

3.  Cigarette smoking among successive birth cohorts of men and women in the United States during 1900-80.

Authors:  J E Harris
Journal:  J Natl Cancer Inst       Date:  1983-09       Impact factor: 13.506

4.  Chapter 2: Birth-cohort-specific estimates of smoking behaviors for the U.S. population.

Authors:  Christy M Anderson; David M Burns; Kevin W Dodd; Eric J Feuer
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

5.  Chapter 7: Description of MISCAN-lung, the Erasmus MC Lung Cancer microsimulation model for evaluating cancer control interventions.

Authors:  F W Schultz; R Boer; H J de Koning
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

6.  Chapter 9: The MGH-HMS lung cancer policy model: tobacco control versus screening.

Authors:  Pamela M McMahon; Chung Yin Kong; Bruce E Johnson; Milton C Weinstein; Jane C Weeks; Angela C Tramontano; Lauren E Cipriano; Colleen Bouzan; G Scott Gazelle
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

7.  Chapter 5: Actual and counterfactual smoking prevalence rates in the U.S. population via microsimulation.

Authors:  Jihyoun Jeon; Rafael Meza; Martin Krapcho; Lauren D Clarke; Jeff Byrne; David T Levy
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

  7 in total
  13 in total

1.  Evaluating the impact of varied compliance to lung cancer screening recommendations using a microsimulation model.

Authors:  Summer S Han; S Ayca Erdogan; Iakovos Toumazis; Ann Leung; Sylvia K Plevritis
Journal:  Cancer Causes Control       Date:  2017-07-12       Impact factor: 2.506

2.  The impact of overdiagnosis on the selection of efficient lung cancer screening strategies.

Authors:  Summer S Han; Kevin Ten Haaf; William D Hazelton; Vidit N Munshi; Jihyoun Jeon; Saadet A Erdogan; Colden Johanson; Pamela M McMahon; Rafael Meza; Chung Yin Kong; Eric J Feuer; Harry J de Koning; Sylvia K Plevritis
Journal:  Int J Cancer       Date:  2017-06-01       Impact factor: 7.396

3.  Comparison of Smoking History Patterns Among African American and White Cohorts in the United States Born 1890 to 1990.

Authors:  Theodore R Holford; David T Levy; Rafael Meza
Journal:  Nicotine Tob Res       Date:  2016-04       Impact factor: 4.244

4.  Disparities of National Lung Cancer Screening Guidelines in the US Population.

Authors:  Summer S Han; Eric Chow; Kevin Ten Haaf; Iakovos Toumazis; Pianpian Cao; Mehrad Bastani; Martin Tammemagi; Jihyoun Jeon; Eric J Feuer; Rafael Meza; Sylvia K Plevritis
Journal:  J Natl Cancer Inst       Date:  2020-11-01       Impact factor: 13.506

5.  Chapter 12: Yale lung cancer model.

Authors:  Theodore R Holford; Keita Ebisu; Lisa McKay; Cheongeun Oh; Tongzhang Zheng
Journal:  Risk Anal       Date:  2012-07       Impact factor: 4.000

6.  A risk-based framework for assessing real-time lung cancer screening eligibility that incorporates life expectancy and past screening findings.

Authors:  Iakovos Toumazis; Oguzhan Alagoz; Ann Leung; Sylvia K Plevritis
Journal:  Cancer       Date:  2021-08-12       Impact factor: 6.860

7.  Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women.

Authors:  Glen B Taksler; Elisabeth F P Peterse; Isarah Willems; Kevin Ten Haaf; Erik E L Jansen; Inge M C M de Kok; Nicolien T van Ravesteyn; Harry J de Koning; Iris Lansdorp-Vogelaar
Journal:  JAMA Oncol       Date:  2021-06-01       Impact factor: 31.777

8.  Tobacco control and the reduction in smoking-related premature deaths in the United States, 1964-2012.

Authors:  Theodore R Holford; Rafael Meza; Kenneth E Warner; Clare Meernik; Jihyoun Jeon; Suresh H Moolgavkar; David T Levy
Journal:  JAMA       Date:  2014-01-08       Impact factor: 157.335

9.  Time trends of Italian former smokers 1980-2009 and 2010-2030 projections using a Bayesian age period cohort model.

Authors:  Giulia Carreras; Giuseppe Gorini
Journal:  Int J Environ Res Public Health       Date:  2013-12-19       Impact factor: 3.390

10.  Population impact of lung cancer screening in the United States: Projections from a microsimulation model.

Authors:  Steven D Criss; Deirdre F Sheehan; Lauren Palazzo; Chung Yin Kong
Journal:  PLoS Med       Date:  2018-02-07       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.